Loading...

Bispecific antibodies in cancer immunotherapy

Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeu...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Eva Dahlén, Niina Veitonmäki, Per Norlén
Format: Artigo
Sprog:Inglês
Udgivet: SAGE Publishing 2018-02-01
Serier:Therapeutic Advances in Vaccines and Immunotherapy
Online adgang:https://doi.org/10.1177/2515135518763280
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!